evipedia.ai
← Back

Phenylpiracetam for Health & Longevity

Evidence Review created on 09/04/2026 using AI4L / Opus 5

Also known as: Fonturacetam, Phenotropil, Carphedon, 4-Phenylpiracetam, Actitropil, Entrop

Motivation

Phenylpiracetam is a laboratory-made compound built by adding a small carbon ring to piracetam, the first substance ever sold as a memory drug. The change makes it much more fat-soluble, so it reaches the brain quickly and works at far smaller amounts. In Russia and a few neighbouring countries it is a licensed prescription medicine for lasting fatigue; almost everywhere else it is an unapproved substance traded informally as a thinking aid. Unlike most of its chemical relatives, it feels stimulating.

Its roots lie in Soviet research on keeping cosmonauts, pilots and soldiers working under extreme strain, and that reputation for boosting stamina eventually led sporting authorities to ban it. Most of the clinical research is still Russian-language work published over four decades and rarely repeated elsewhere, while the compound has quietly become a fixture of the online market for brain supplements.

This review examines what the human and laboratory evidence shows about phenylpiracetam’s effects, how it appears to work, the doses and treatment courses used in clinical practice, its side effects and interactions, the independence and quality of the research behind it, and the practical and legal position it occupies outside Russia.

Benefits - Risks - Protocol - Conclusion

High-level sources that discuss phenylpiracetam in depth, covering its pharmacology, its regulatory position as a nootropic (a compound taken to sharpen thinking), and the quality of the products sold under its name.

None of the six priority sources (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has published content on phenylpiracetam; searches of each platform and of the open web returned no material naming the compound, most likely because it is an unapproved drug rather than a supplement and therefore falls outside their editorial scope.

Grokipedia

  • Phenylpiracetam

    A dedicated encyclopaedic entry covering the compound’s chemistry, Soviet development history, pharmacology, legal status by country and doping history, useful for orienting quickly before reading the primary literature.

Examine

No Examine article on phenylpiracetam exists; a direct search of examine.com returns no results for the term.

Phenylpiracetam is a prescription medicine in Russia and several neighbouring countries and an unapproved drug elsewhere, not a lawful dietary ingredient. Examine.com covers supplements and does not typically cover prescription medications, which explains the absence.

ConsumerLab

No ConsumerLab article on phenylpiracetam exists; a direct search of consumerlab.com returns no product review or dedicated report on the compound.

Phenylpiracetam is a prescription medicine in Russia and an unapproved drug in the United States, not a lawful supplement ingredient. ConsumerLab reviews dietary supplements and does not typically cover prescription medications, which explains the absence.

Systematic Reviews

A PubMed search of the intervention and its synonyms, restricted to systematic reviews and meta-analyses, yields a single pooled analysis, and it concerns asthenia (persistent fatigue that rest does not relieve).

Phenylpiracetam involves a clear trade-off between a claimed anti-fatigue benefit and the risks of stimulant exposure, dependence potential and an unregulated supply. Only the benefit side is represented above: no systematic review or meta-analysis of phenylpiracetam’s adverse effects, abuse liability or long-term safety has been published, so the principal-risk side of the trade-off is unrepresented in this section. Fewer than five papers are listed because only one qualifying paper exists; the list was not padded with class-level piracetam reviews.

Mechanism of Action

Phenylpiracetam is piracetam with a phenyl group — a six-carbon ring — added to its core ring. This makes it far more fat-soluble, so it crosses the blood-brain barrier (the filter separating blood from brain tissue) and is active in animal models at a thirtieth to a sixtieth of a piracetam dose.

It is sold as a racemic mixture: equal parts of two mirror-image forms. Radioligand screening in mice identified the dopamine transporter (DAT, the pump that clears dopamine — the brain’s drive-and-reward messenger — out of the synapse) as the only significant target of R-Phenylpiracetam. Blocking that pump raises dopamine signalling, matching the stimulant-like profile. Separating the two forms showed increased movement and antidepressant-like effects from both, but the memory effect from R-Phenylpiracetam alone.

Two mechanistic accounts compete. The original Soviet account is glutamatergic: the racetam family (compounds built on piracetam’s ring) is held to modulate AMPA and NMDA glutamate receptors (the brain’s main excitatory signalling system), explaining the anticonvulsant and memory findings. The dopaminergic account better explains alertness, drive and reduced fatigue but not the anticonvulsant action. Neither is settled.

Oral absorption is near-complete, peak blood levels arrive within about an hour, and the elimination half-life is three to five hours. The compound is largely not metabolised — no cytochrome P450 (CYP, the liver’s main drug-processing enzyme family) pathway has been characterised — and leaves the body mostly unchanged, about 40% in urine. It has no meaningful affinity for norepinephrine or serotonin transporters.

Historical Context & Evolution

Phenylpiracetam was synthesised in the Soviet Union and first characterised pharmacologically in 1983, when Bobkov and colleagues compared it with piracetam. They reported that it drove reward-based task performance more strongly, reversed the behavioural depression caused by diazepam, suppressed post-rotational eye-jerking and prevented retrograde amnesia (loss of memories formed before an injury); unlike piracetam it also had a distinct anticonvulsant action, and at high doses it depressed rather than stimulated behaviour. The original brief was not public cognitive enhancement but sustaining performance under extreme operational stress, and the compound entered use in Soviet space and military programmes.

It reached the civilian Russian market as Phenotropil, characterised in large part by V. I. Akhapkina, and was later manufactured in Latvia as Entrop and marketed in Russia as Actitropil. Sporting authorities moved first internationally: carphedon became the first nootropic added to the prohibited list in 1998.

Interest for health optimisation followed from three features: potency at 100–200 mg, a subjectively stimulant effect unusual in this drug family, and low-cost availability once online vendors began importing bulk powder in the 2000s.

The mechanistic picture has since shifted rather than been overturned. Latvian pharmacologists reframed the compound in the 2010s as a dopamine transporter blocker rather than a classical racetam. The Soviet findings have been neither replicated nor refuted by independent Western groups, so their standing rests on their own methods rather than on later confirmation or dismissal.

Expected Benefits

High 🟩 🟩 🟩

Reduction of Persistent Fatigue (Asthenia)

Asthenia — persistent fatigue that rest does not relieve — is the indication with the most human data. A 2025 systematic review and meta-analysis pooled 11 studies and 549 patients treated with 200 mg daily for one month, reporting large falls in fatigue scores alongside gains in sleep and mood. Every included study was Russian, most were open-label, and several sit within manufacturer-linked research programmes, so publication and sponsor bias are unquantified. The direction is consistent; the size is probably inflated.

Magnitude: Scores on the Multidimensional Fatigue Inventory (MFI-20, a 20-item self-report fatigue questionnaire) fell by a mean of 16.3 points (95% confidence interval, the range within which the true value probably lies: 8.85 to 23.85) by day 30 across 549 patients.

Medium 🟩 🟩

Neurological, Motor and Cognitive Recovery After Brain Injury

In a controlled trial of 400 patients recovering from ischaemic stroke, 200 received three courses of 400 mg daily across the first year alongside standard rehabilitation; recovery of neurological function and of independence in daily activities, on the Barthel, Lindmark, Scandinavian and Merton and Sutton scales, was significantly better than in controls. An uncontrolled series in established brain injury reported parallel gains in limb weakness, coordination, memory and attention. Neither was blinded and neither has a counterpart outside Russia; the signal is in damaged brains, not healthy ones.

Magnitude: Recovery favoured phenylpiracetam at p < 0.0001 (p, the probability that a difference this large would arise by chance alone) on all four scales after three 400 mg/day courses in the first post-stroke year; the published report gives no effect size, so the literature reports no outcome figure.

Add-On Seizure Control in Focal Epilepsy

A double-blind, placebo-controlled randomised controlled trial (RCT — a study in which participants are assigned to real or dummy treatment by chance) in 90 adults with symptomatic focal epilepsy added 100 or 200 mg daily to standard antiepileptic drugs. Seizure frequency fell and cognitive scores improved in patients without epileptic abnormalities on brain-wave recording. This is the only blinded, placebo-controlled trial in the phenylpiracetam literature; it is small, single-centre and unreplicated, and it failed to offset the drawbacks of standard therapy in 40% of patients.

Magnitude: Seizure frequency fell and cognitive scores rose on 100–200 mg/day added to standard therapy over the trial period; the published report gives no seizure-reduction percentage or effect size, so the literature reports no outcome figure.

Reduction of Anxiety and Depressive Symptoms

In a controlled trial in cardiovascular patients with mild neurotic, stress-induced and depressive disorders, 35 patients took phenotropil for 12 weeks against 35 comparators, rated on the Hamilton Depression Rating Scale (HDRS, a clinician-scored measure of depression severity) and the Clinical Global Impression scale. Symptoms improved and tolerability was satisfactory, but the anxiety-reducing effect faded after four to eight weeks. Depression is an approved indication in Russia; this is the only controlled human trial of the outcome.

Magnitude: Symptom scores improved over 12 weeks on the Hamilton and Clinical Global Impression scales, with the anxiety-reducing component fading between weeks four and eight; the published report gives no effect size, so the literature reports no outcome figure.

Low 🟩

Speculative 🟨

Subjective Alertness, Drive and Focus in Healthy Adults

No trial has tested phenylpiracetam in healthy people. The basis is the dopamine transporter mechanism and consistent user report of stimulation, motivation and sharper attention within an hour of dosing.

Physical Endurance and Stress Tolerance

Developed to sustain performance under operational stress and prohibited in sport as carphedon from 1998. No controlled human trial has measured endurance or output; the basis is regulatory judgement and user report.

Reduced Body-Weight Gain and Better Glucose Handling

In obese mice and rats, S-Phenylpiracetam cut weight and fat gain and lowered blood glucose without stimulating movement. No human metabolic study exists, so the basis is animal work only.

Anti-Inflammatory Neuroprotection

R-Phenylpiracetam reduced inflammatory gene expression, paw swelling and pain responses in mouse models of inflammation. No human inflammatory or neuroprotection endpoint has been tested, so the basis is animal work alone.

Benefit-Modifying Factors

  • COMT Val158Met genotype: COMT (catechol-O-methyltransferase, the enzyme that clears dopamine from the frontal brain) Met/Met carriers already run high frontal dopamine and may overshoot into anxiety; Val/Val carriers plausibly gain most. Untested for this compound.

  • Dopamine transporter gene variants: SLC6A3 (the gene encoding the pump this drug blocks) carries a common repeat variant that alters transporter density. Carriers of the low-expressing form have fewer targets available and may respond less. Untested here.

  • Baseline fatigue level: the pooled trials enrolled patients with marked, measurable fatigue. Someone already sleeping well and recovering fully has far less room to improve, so a ceiling effect should be expected in an optimised person.

  • Pre-existing conditions: untreated hypothyroidism, iron deficiency, sleep apnoea and depression are common competing causes of fatigue. Where one of these is driving symptoms, a dopaminergic stimulant masks rather than resolves the problem.

  • Known sex-based differences: none have been reported. The pooled trials do not separate results by sex, and no study compares blood levels in men and women, so any sex difference in response or exposure is currently unknown.

  • Age-related considerations: the observational asthenia programme found faster and larger fatigue reduction in younger patients. Adults in their sixties and beyond also carry more cardiovascular contraindications and slower renal clearance of an unchanged drug.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Stimulant-Type Adverse Effects: Insomnia, Agitation and Raised Blood Pressure

The dopaminergic, stimulant-like action produces a predictable pattern: difficulty falling asleep, restlessness, irritability and, in some people, anxiety, facial flushing or raised blood pressure and heart rate. Russian prescribing information labels the last three as first-week effects. The 2025 meta-analysis of 549 patients reported adverse events in 5.5% at 200 mg daily, all transient. That figure comes from supervised patients on one fixed dose; self-directed users take higher, later doses and commonly co-administer other stimulants, where insomnia and additive cardiovascular load dominate. Severity is mild and reversible on stopping.

Magnitude: Adverse events occurred in 5.5% of 549 patients across 11 pooled studies at 200 mg daily for one month, all transient and resolving within a week of continued dosing.

Medium 🟥 🟥

Undeclared Drugs and Inaccurate Doses in Consumer Products

Because phenylpiracetam is not a lawful supplement ingredient anywhere in the West, the retail supply is unregulated. Analysis of ten cognitive-enhancement products labelled as containing racetams found five unapproved drugs, undeclared additions such as phenibut and picamilon, declared ingredients absent, and most stated quantities inaccurate. A 2025 survey by twelve official medicines-control laboratories intercepted phenylpiracetam as bulk raw material on the illegal market. The exposure risk is often the co-ingested drug, not the labelled one.

Magnitude: 75% (9 of 12) of declared drug quantities in tested cognitive-enhancement products were inaccurate, with individual products containing up to four unapproved drugs and up to four times a pharmaceutical dose.

Anti-Doping Rule Violations in Tested Athletes

Fonturacetam was the first nootropic prohibited in sport, banned in 1998 and carried forward onto the list the World Anti-Doping Agency has maintained since it was founded the following year — a list whose associated testing and certification industry earns revenue from its expansion. Urine screening methods are long established, and positive tests continue to end careers. The risk applies to anyone in a tested pool regardless of dose or intent, and contaminated pre-workout products are a documented route to an unintentional positive.

Magnitude: Any use within the detection window — a few days after the last dose, given a three-to-five-hour half-life — produces a positive test in a tested athlete; the literature reports no outcome figure for violation rates.

Low 🟥

Loss of Effect with Continued Daily Use

Clinical use is built around fixed one-month courses at 200 mg daily, and every study in the pooled analysis followed that pattern. The only 12-week trial reported the anxiety-reducing effect declining after four to eight weeks. The claim that stimulation fades within days rests on user report.

Magnitude: The anxiety-reducing effect declined between weeks four and eight in the single 12-week trial; no trial has dosed beyond three months, and the published report gives no decay rate, so the literature reports no outcome figure.

Speculative 🟨

Dependence and Compulsive Redosing

Blocking the dopamine transporter is the shared mechanism of cocaine and methylphenidate, raising a theoretical misuse risk. No human dependence or abuse-liability study of phenylpiracetam exists; the basis is mechanism alone.

Rebound Fatigue and Low Mood After Stopping

Stopping a dopaminergic stimulant can be followed by a temporary dip in drive and energy. No trial has looked for this after phenylpiracetam; the basis is class mechanism and isolated user report.

Risk-Modifying Factors

  • Dopamine-pathway polymorphisms: DRD2/ANKK1 Taq1A (a variant that lowers dopamine receptor numbers) and SLC6A3 repeat variants plausibly shift both the stimulant response and the misuse risk. No gene-guided dosing study of this compound exists.

  • Baseline blood pressure and resting heart rate: these two markers decide tolerability. Someone starting above 140/90 mmHg, or with a resting rate above 80 beats per minute, has the least headroom for a stimulant.

  • Known sex-based differences: none are reported. No study separates adverse events by sex and no comparison of blood levels exists, so the possibility of higher exposure per kilogram in women is untested rather than excluded.

  • Pre-existing health conditions: anxiety disorders, bipolar disorder, psychosis, uncontrolled hypertension, established coronary disease and insomnia all amplify the stimulant side of the profile. Renal impairment raises exposure to a drug excreted mostly unchanged.

  • Age-related considerations: adults past sixty carry more untreated hypertension and atherosclerosis (fatty narrowing of arteries), sleep more lightly, and clear the drug more slowly, so the same dose delivers more exposure.

Key Interactions & Contraindications

  • Dopaminergic stimulants (amphetamine, lisdexamfetamine, methylphenidate, modafinil): caution to avoid. Additive dopamine transporter blockade risks agitation, tachycardia (a fast heart rate) and hypertension. Combination is not supported; where a stimulant is already prescribed, phenylpiracetam is redundant and additive.

  • Monoamine oxidase inhibitors (MAOIs — antidepressants such as phenelzine, tranylcypromine, selegiline): absolute contraindication. Blocking dopamine reuptake while blocking its breakdown risks a dangerous blood-pressure surge. Separation by timing does not mitigate; a two-week washout after an irreversible MAOI is required.

  • Antipsychotics (haloperidol, risperidone, olanzapine): caution, with monitoring. Phenylpiracetam raises dopamine signalling while these drugs block it, so each may blunt the other. Animal work shows it counteracts haloperidol-induced rigidity. Self-directed addition to prescribed antipsychotic therapy is unstudied and falls to specialist oversight.

  • Antihypertensives (amlodipine, lisinopril, bisoprolol): monitor. A stimulant can offset blood-pressure control and produce readings above target. Mitigation is home monitoring twice weekly for the first month and dose review with the prescriber, not stopping the antihypertensive.

  • Antiepileptic drugs (valproate, carbamazepine, levetiracetam): monitor. The one blinded trial added phenylpiracetam to standard therapy without loss of seizure control, but the interaction is unstudied outside that setting and self-directed use alongside seizure medication warrants specialist oversight.

  • Over-the-counter stimulants and decongestants (caffeine, pseudoephedrine, phenylephrine): caution. Additive rises in heart rate, blood pressure and sleep-onset time. Mitigation is to cap total caffeine at 200 mg on dosing days and avoid decongestants entirely.

  • Supplements with additive stimulant or dopaminergic effects (yohimbine, higenamine, synephrine, L-Tyrosine, levodopa-containing Mucuna pruriens): caution. These load the same pathway and the same adverse effects. Mitigation is to run only one dopaminergic or stimulant agent at a time.

  • Choline donors (alpha-GPC, citicoline, choline bitartrate): alpha-GPC (alpha-glycerylphosphorylcholine) and the others carry no interaction risk and are used to blunt racetam-associated headache. Evidence is anecdotal, mechanism plausible via acetylcholine supply. Typical practice is 300 mg alpha-GPC per dose.

  • Phenibut and other GABA-active compounds (GABA — gamma-aminobutyric acid, the brain’s main calming messenger): caution to avoid. Frequently co-packaged in the same products and independently associated with dependence and withdrawal, so combining them compounds two poorly characterised risks.

  • Other interventions — sleep restriction and hard training blocks: caution. Stimulants mask the fatigue signal that regulates recovery, so an overreaching training block or chronic short sleep can progress further before it is noticed. Mitigation is objective sleep and heart-rate-variability tracking.

Populations who should avoid Phenylpiracetam:

  • Athletes subject to anti-doping testing in any tested pool, including masters, amateur and military competition
  • Uncontrolled or severe hypertension (blood pressure at or above 180/110 mmHg)
  • Recent myocardial infarction (heart attack) within 90 days, unstable angina (chest pain at rest), or uncontrolled arrhythmia (irregular heartbeat)
  • Psychotic disorders, bipolar I disorder in or near a manic phase, and panic disorder
  • Severe hepatic impairment (Child-Pugh Class C, the most advanced grade of liver failure)
  • Severe renal impairment (eGFR — estimated glomerular filtration rate, a measure of kidney filtering capacity — below 30 mL/min/1.73 m²)
  • Pregnancy and breastfeeding, and anyone under 18 years of age
  • Anyone taking a monoamine oxidase inhibitor, or within two weeks of stopping one

Risk Mitigation Strategies

  • Morning-only dosing: taking the full daily amount before 12:00 keeps the three-to-five-hour half-life clear of the sleep window. This directly prevents insomnia, the most frequent adverse effect and the one that erodes the fatigue benefit.

  • Low starting dose with stepwise titration: starting at 100 mg and holding for three days before considering 200 mg identifies over-responders early and prevents the agitation, flushing and tachycardia seen at full dose in sensitive people.

  • Fixed-course use rather than continuous dosing: limiting use to the 30-day courses studied in the trials, then stopping, mitigates loss of effect with continued use and avoids open-ended exposure for which no long-term safety data exist.

  • Blood-pressure logging during the first month: home readings twice weekly, seated after five minutes’ rest, catch a sustained rise above 140/90 mmHg before it becomes cardiovascular strain. Two consecutive readings above it mark the discontinuation point.

  • Single-ingredient product with a lot-specific certificate of analysis: buying only material with third-party identity and purity testing for the exact lot mitigates the documented risk of undeclared phenibut, picamilon or vinpocetine and of quantities several-fold off label.

  • Total stimulant budget: counting phenylpiracetam against all other stimulant intake and capping caffeine at 200 mg on dosing days prevents the additive rise in heart rate, blood pressure and sleep-onset latency from co-administered agents.

  • No use in a tested competition pool: verifying status against the current prohibited list before any use is the only mitigation for the anti-doping risk, which no dose reduction or timing strategy reduces.

Therapeutic Protocol

  • Standard Russian clinical course: 100–200 mg daily for 30 days is the regimen used across the pooled asthenia trials; stroke rehabilitation used 400 mg daily in three separate courses across the first post-stroke year.

  • Competing approach — self-directed intermittent use: the online cognitive-enhancement community uses 100–200 mg only on demanding days rather than daily. Neither approach has been compared against the other; both are presented here without preference.

  • Who popularised each: the fixed-course clinical protocol traces to Bobkov’s original Soviet pharmacology group and to V. I. Akhapkina, who characterised Phenotropil. The intermittent pattern arose from vendor and community practice, with no clinical origin.

  • Best time of day: morning, before 12:00. Onset is under an hour and stimulation persists for several hours; afternoon dosing is the main avoidable cause of the insomnia reported in trials and by users.

  • Half-life: roughly three to five hours, with oral absorption close to complete and peak blood levels within about an hour. Excretion is mostly unchanged, so hepatic enzyme induction or inhibition is not expected to matter.

  • Single versus split dosing: the trials used a single or twice-daily split of the 200 mg total. Splitting into 100 mg on waking and 100 mg before noon smooths the peak; both halves must precede early afternoon.

  • Genetic polymorphisms influencing dose: COMT and SLC6A3 variants plausibly shift the dose–response, and DRD2/ANKK1 Taq1A may shift misuse risk. No gene-guided dosing data exist, so genotype cannot currently guide dose selection.

  • Known sex-based differences: none are established. No trial reports efficacy or dosing by sex, and no comparison of blood levels exists, so the same dose ranges are used for men and women by default rather than by evidence.

  • Age-related considerations: older adults showed slower fatigue improvement in observational data and clear the unchanged drug more slowly. Starting at 100 mg and holding there is the conservative approach past sixty.

  • Baseline biomarkers influencing response: a documented, measurable fatigue burden predicts the largest change; normal baseline energy predicts little. Baseline blood pressure and resting heart rate determine how much stimulant load is tolerable.

  • Pre-existing conditions influencing response: untreated thyroid disease, iron deficiency, sleep apnoea and depression each produce fatigue that a dopaminergic stimulant masks without correcting, so protocols identify and address them before a course begins.

Discontinuation & Cycling

  • Intended duration: short-term, not lifelong. Every clinical protocol is a defined course of one to three months for a specific indication; no approved labelling, trial or guideline supports open-ended daily use in a healthy person.

  • Withdrawal effects: none are documented in the trial literature or in Russian prescribing information. Users report a temporary dip in drive and energy after stopping, consistent with any dopaminergic stimulant, but this has never been formally measured.

  • Tapering: no taper protocol exists and none appears necessary given the absence of documented withdrawal. Trials stopped the drug abruptly at the end of each 30-day course without reported problems.

  • Cycling: the fixed-course pattern is itself a cycle. Common self-directed practice is one to two weeks on and an equal period off, intended to preserve the stimulant effect; no study has tested whether cycling preserves efficacy.

Sourcing and Quality

  • Pharmaceutical-grade options: the only products manufactured to a pharmacopoeial standard are the Russian and Latvian prescription medicines Phenotropil, Actitropil and Entrop. These are not lawfully available in the United States, the United Kingdom or the European Union.

  • Third-party testing is the deciding factor: for any consumer-market powder, a lot-specific certificate of analysis from an independent laboratory covering identity, purity and heavy metals is the minimum. Vendor-generic certificates that do not name the lot are not evidence.

  • Formulation: the racemic mixture is the only form sold and the only form clinically studied. Single mirror-image R- or S-material appears in research settings only; anything marketed as an isolated single form is therefore unverified.

  • Multi-ingredient blends concentrate the adulteration risk: the documented adulteration problem is concentrated in combination “nootropic” products, where undeclared phenibut, picamilon, vinpocetine or omberacetam have been found. A single-ingredient powder narrows the exposure to one compound.

  • Compounding pharmacies: United States compounding pharmacies cannot supply phenylpiracetam because it is an unapproved drug rather than a recognised active ingredient. There is no regulated domestic route in most Western jurisdictions.

Practical Considerations

  • Time to effect: stimulant effects are felt within about an hour of the first dose. The fatigue benefit measured in trials was assessed at 30 days, with improvement reported from the end of the first month of treatment.

  • Common pitfall — afternoon dosing: the single most frequent self-inflicted problem. Taking a second dose after midday delays sleep onset, which then worsens the fatigue the compound was taken to address.

  • Common pitfall — treating it as a daily supplement: all clinical data come from bounded courses. Open-ended daily use exceeds every studied protocol and is where tolerance and unknown long-term effects become relevant.

  • Common pitfall — skipping the underlying cause: using a stimulant while an untreated thyroid, iron, sleep-apnoea or mood problem drives the fatigue postpones the diagnosis that would actually resolve it.

  • Regulatory status: unapproved in the United States. The Food and Drug Administration has stated in warning letters to nootropic retailers that phenylpiracetam is not a dietary supplement or conventional food and is an unapproved new drug.

  • Cost, accessibility and payer incentives: the compound is inexpensive, and outside Russia no insurer or health system pays for it, so no institutional payer has a stake in favouring or suppressing it. The structural bias here is commercial, not institutional.

Interaction with Foundational Habits

  • Sleep: direct and blunting. Dopamine transporter blockade with a three-to-five-hour half-life delays sleep onset and shortens total sleep when dosing runs past midday; insomnia is the dominant user complaint. In practice, dosing is confined to before 12:00, and courses are not started in a week already carrying sleep debt.

  • Nutrition: indirect. No food interaction or nutrient depletion is documented, and absorption is near-complete with or without food. Many users co-dose a choline donor such as alpha-GPC on the anecdotal grounds that racetams increase acetylcholine demand and can cause headache; the mechanism is plausible and the evidence is user report.

  • Exercise: potentiating for perceived output, with a specific hazard. Stimulants raise perceived capacity and mask the fatigue signal governing recovery, so an overreaching training block can progress further before it is noticed. Animal work found no movement stimulation from the S-form, so the training effect is likely central rather than muscular.

  • Stress management: direct and bidirectional. The compound was developed to sustain function under operational stress and calms anxiety in animal models, yet irritability and anxiety are among its reported adverse effects in people. Practical consideration: it suits acute, bounded demands and works against a chronic-stress state that needs downregulation.

Monitoring Protocol & Defining Success

Baseline testing before a course captures both the target symptom and the stimulant risk. It comprises seated blood pressure and resting heart rate on three separate mornings and a panel covering liver enzymes, kidney function, fasting glucose and glycated haemoglobin, since the drug leaves the body largely unchanged via the kidneys and animal work showed glucose effects. Fatigue is scored formally rather than by impression, and competing causes are excluded first by thyroid, iron and vitamin B12 testing.

Ongoing monitoring is light because courses are short. Blood pressure and heart rate are repeated twice weekly through the first month, fatigue is re-scored at day 30 against baseline, and the laboratory panel is repeated only where courses recur, at roughly every six months. Sleep is tracked continuously with a wearable throughout each course.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Seated blood pressure 105/65 to 120/75 mmHg Detects a stimulant-driven blood-pressure rise Seated, after five minutes’ rest, same arm; conventional hypertension thresholds are higher at 130/80 mmHg (United States) and 140/90 mmHg (Europe)
Resting heart rate 50–65 beats per minute Detects fight-or-flight load from the drug Measured on waking, before caffeine; conventional reference range extends to 100 beats per minute, which is far too permissive as a change signal
Total sleep time and time taken to fall asleep 7–9 hours; onset under 20 minutes Insomnia is the most frequent adverse effect Wearable or diary; compare to the individual’s own pre-course average rather than to a population norm
MFI-20 fatigue score No established target; track the change from the individual’s own baseline, as the pooled trials did Quantifies the primary claimed benefit instead of relying on impression Multidimensional Fatigue Inventory, 20 self-report items across five subscales; administer at the same time of day each time
ALT 10–20 U/L Screens liver tolerability before and between courses ALT is alanine aminotransferase, an enzyme released when liver cells are stressed; fasting preferred; conventional upper limits of 40–55 U/L are much looser than the functional target
eGFR Above 90 mL/min/1.73 m² The drug leaves the body largely unchanged via the kidneys, so clearance sets exposure Paired with serum creatinine and urine albumin-to-creatinine ratio; conventional concern starts only below 60 mL/min/1.73 m²
Fasting glucose 75–86 mg/dL Animal work showed glucose and fat-mass effects that have never been tested in people Fasting 10–12 hours; best paired with glycated haemoglobin and drawn in the morning; the conventional normal range runs to 99 mg/dL, far looser than the functional target
HbA1c Below 5.4% Confirms whether any fasting-glucose shift is real or incidental HbA1c is glycated haemoglobin, reflecting average blood sugar over about three months; no fasting needed; unreliable in anaemia or recent blood loss; conventional prediabetes threshold is 5.7%
TSH 0.5–2.0 mIU/L Excludes an underactive thyroid as the competing cause of the fatigue TSH is thyroid-stimulating hormone; drawn in the morning and best paired with free T4 (thyroxine) and free T3 (triiodothyronine, the active thyroid hormone); the conventional upper limit of 4.0–4.5 mIU/L misses milder underactivity
Ferritin 50–150 ng/mL (menstruating women 50–100 ng/mL) Excludes iron deficiency, which causes fatigue long before anaemia appears Ferritin is the iron storage protein and rises with inflammation, so it is read alongside C-reactive protein; conventional deficiency cut-offs start only below 15–30 ng/mL
Vitamin B12 500–900 pg/mL Excludes a B12 deficit producing fatigue and cognitive complaints Best paired with methylmalonic acid where the result is borderline; the conventional lower limit of about 200 pg/mL leaves functional deficiency undetected

Qualitative markers matter more here than laboratory values, because the target symptom is subjective:

  • Energy through the afternoon rather than only in the first hours after dosing
  • Motivation to start tasks, which is the effect users most often describe
  • Sleep quality and time taken to fall asleep, tracked nightly
  • Irritability and anxiety, which mark the point where dose exceeds benefit
  • Cognitive clarity and the ability to hold attention on a single task

Emerging Research

  • No registered trial exists: a ClinicalTrials.gov search for phenylpiracetam, fonturacetam, phenotropil and carphedon returns no study. All human evidence sits in the Russian-language literature outside the international registry system, which is itself the single largest gap in the evidence base.

  • Nearest registered racetam trial: NCT06479629 is a Phase 4 randomised, placebo-controlled trial of piracetam 800 mg three times daily in 60 patients with diabetic peripheral neuropathy, with pain, cognition and blood biomarker endpoints. It tests the parent compound, not phenylpiracetam.

  • Post-viral fatigue and cognition: NCT07722000 randomised 90 post-COVID patients to Ginkgo biloba, piracetam, or both, with a cognitive screening score as the primary endpoint and fatigue severity as a secondary endpoint. Completed 2023; results not yet posted.

  • Single-form development could strengthen the case: the Latvian work on S-Phenylpiracetam and body weight and on R-Phenylpiracetam and inflammation points toward the two mirror-image forms being developed as separate drugs with cleaner profiles than the racemic mixture.

  • Independent replication could weaken the case: the entire benefit claim rests on the pooled Russian asthenia data of Devlikamova & Safina, 2025. A blinded trial run outside that research ecosystem is the single study most likely to change the picture in either direction.

  • Abuse liability is the untested risk: no formal abuse-liability or dependence study exists, despite the dopamine transporter mechanism identified by Zvejniece et al., 2020 in mouse target profiling. A negative finding would remove the main speculative objection; a positive one would reclassify the compound.

  • Supply-side surveillance is expanding: the medicines-control laboratory network survey of Vanhee et al., 2025 establishes ongoing monitoring of illicit nootropic supply across Europe and Australia, which will progressively quantify how often consumer material is misdeclared.

Conclusion

Phenylpiracetam is a Soviet-era modification of the first drug ever marketed to sharpen thinking, potent enough to work at a fraction of the parent dose and stimulating in a way its chemical relatives are not. That stimulation appears to come from blocking the pump that clears the brain’s drive-and-reward messenger, although the older explanation based on the brain’s main excitatory signalling system has not been displaced.

The strongest human signal is a reduction in persistent, unrefreshing fatigue over month-long courses. Beneath it sit a single blinded trial in epilepsy, one controlled stroke-rehabilitation trial, one controlled trial in mood and anxiety symptoms, and a body of uncontrolled reports. Almost all of this is Russian-language work, much of it produced or funded by the companies that sell the drug, and none of it has been repeated by independent groups elsewhere, so the direction of the effect is more credible than its size. The anti-doping and product-testing sources that shape its risk picture carry their own commercial interests.

The short-term side-effect profile looks mild and reversible, dominated by sleeplessness and irritability. The larger practical hazards lie outside the drug itself: the retail supply outside Russia is unregulated and often misdeclared, tested athletes face a ban for any use, and nothing is known about taking it for years. Fading effect and dependence remain plausible from how it works, but neither has been tested.

Top - Benefits - Risks - Protocol